Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CVI-HBV-002 in Adults
NCT06147895Phase 1Completed
- Sponsor
- AriBio Lab
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CVI-HBV-002 in hepatitis B (HBV) (2 arms), sponsored by AriBio Lab. Primary endpoints: Immediate adverse events, Solicited local and systemic signs and symptoms and 3 more. Started Sep 2021; status: completed.
02
Drugs
CVI-HBV-002
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT06147895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06147895.